Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24123

Title: Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
Authors: Bonne, Lawrence
Verslype, Chris
Laenen, Annouschka
Cornelissen, Sandra
Deroose, Christophe M.
Prenen, Hans
Vandecaveye, Vincent
Van Cutsem, Eric
Maleux, Geert
Issue Date: 2017
Citation: RADIOLOGY AND ONCOLOGY, 51(1), p. 74-80
Abstract: Background. The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) microspheres. Patients and methods. Patients with neuroendocrine liver metastases who underwent hepatic transarterial chemoembolization using doxorubicin-eluting SAP-microspheres (50-100 pm Hepasphere/Quadrasphere Microsphere particles, Merit Medical, South Jordan, Utah, USA) were included in this study. Pre- and post-procedure imaging studies were evaluated to assess short and intermediate-term tumour response using modified RECIST criteria. Symptom relief and procedure-related complications were evaluated. Results. A total of 27 embolization procedures were performed on 17 patients. Twelve of 17 patients (70%) were symptomatic, including carcinoid syndrome (n = 8) and severe, uncontrollable hypoglycemia (n = 4). Eight of 12 patients (67%) had complete symptom relief, and the remaining 4 (33%) had partial relief. One patient developed ischemic cholecystitis (6%). No other hepatobiliary complications occurred. Short-term and intermediate-term imaging follow-up was available for 15/17 patients (88%) and 12/14 patients (86%) respectively. At short-term follow-up (< 3 months), 14 patients (93%) showed partial response and the remaining patient had progressive disease (7%). At intermediate-term imaging follow-up (> 3 months), partial response, stable disease and progressive disease were found respectively in 7 (58%), 3 (25%) and 2 (17%) patients. Conclusions. Chemoembolization with doxorubicin-eluting SAP-microspheres is a safe and effective treatment option for neuroendocrine liver metastases and is associated with a low complication rate. In particular, no clinically evident liver necrosis or bile duct complications were encountered.
Notes: [Bonne, Lawrence; Cornelissen, Sandra; Vandecaveye, Vincent; Maleux, Geert] Univ Hosp Leuven, Dept Radiol, Herestr 49, B-3000 Leuven, Belgium. [Verslype, Chris; Prenen, Hans; Van Cutsem, Eric] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium. [Laenen, Annouschka] Katholieke Univ Leuven, Interuniv Ctr Biostat & Stat Bioinformat, Leuven, Belgium. [Laenen, Annouschka] Univ Hasselt, Hasselt, Belgium. [Deroose, Christophe M.] Univ Hosp Leuven, Dept Nucl Med, Leuven, Belgium.
URI: http://hdl.handle.net/1942/24123
DOI: 10.1515/raon-2017-0007
ISI #: 000397080400010
ISSN: 1318-2099
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version511.31 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.